From the Laboratory of AIDS Immunopathogenesis, Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland.
HIV-1- and cytomegalovirus (CMV)-specific CD4 T-cell-mediated antiviral immunity was evaluated by assessing the frequency of interleukin 2 (IL-2)- and interferon 
(IFN-)-secreting cells following antigen-specific stimulation in blood and lymph node. HIV-1-infected subjects with progressive disease at early stage of infection with no previous history of antiretroviral therapy (ART), subjects with nonprogressive disease, and HIV-negative subjects were studied. On the basis of the ability to secrete IL-2 and IFN-, 3 functionally distinct populations of CD4 T cells were identified: (1) IL-2-secreting cells; (2) IL-2/IFN--secreting cells; and (3) IFN--secreting cells. CMV-specific CD4 T cells were almost equally distributed within the 3 functionally distinct cell populations in the 3 study groups as well as HIV-1-specific CD4 T cells in subjects with nonprogressive disease. However, a skewing toward IFN--secreting cells (70% of HIV-1-specific CD4 T cells) was observed in subjects with progressive disease, and IL-2- and IL-2/IFN--secreting cells were almost absent. The frequencies of IL-2- and of IL-2/IFN--secreting HIV-1-specific CD4 T cells were negatively correlated with the levels of viremia. Interestingly, prolonged ART was able to correct the skewed representation of different populations of HIV-1-specific CD4 T cells but was associated with only a partial recovery of IL-2-secreting cells. These results indicate that the composition of the pool of functionally distinct virus-specific CD4 T cells is important for virus control. (Blood. 2004;103:966-972)
Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation
17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated constitutively activated KIT protein in human mast cells
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
A potential therapeutic role for small nonpeptidyl compounds that mimic human granulocyte colony-stimulating factor
Activated Fps/Fes partially rescues the in vivo developmental potential of Flk1-deficient vascular progenitor cells
Activated Fps/Fes to the rescue
Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning
An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13
Assessment of removal of human cytomegalovirus from blood components by leukocyte depletion filters using real-time quantitative PCR
Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation